IP Library › Granted Patent US 12,599,673
Granted Patent B2
US 12,599,673 · App. 17/470,121 · Granted Apr 14, 2026

Techniques for enhancing the selectivity and efficacy of antimicrobial and anticancer polymer agents

Inventors: James L. Hedrick (Pleasanton, CA); Nathaniel H. Park (San Jose, CA); Yi Yan Yang (Singapore, SG); Zhi Xiang Voo (Singapore, SG)
Assignees: INTERNATIONAL BUSINESS MACHINES CORPORATION; Agency for Science, Technology and Research
A61K47/59A61K31/155A61K31/4188A61K47/55A61K47/551
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,599,673
App. No.
17/470,121
Granted
Apr 14, 2026
Kind
B2
Abstract

The subject disclosure is directed to techniques for enhancing the selectivity and efficacy of therapeutic polymers against a broad spectrum of pathogens and cancer cell lines. According to an embodiment, a method is provided that comprises forming a therapeutic polymer based on polymerization of a plurality of therapeutic monomers, wherein the therapeutic polymer provides a therapeutic functionality. The method further comprises attaching biotin to the therapeutic polymer, resulting in a biotin-functionalized therapeutic polymer, wherein the biotin-functionalized therapeutic polymer provides greater therapeutic efficacy relative to the therapeutic polymer.

Claims (43)

1 . A therapeutic agent, comprising:

a cationic polymer and an anionic polymer,

wherein the cationic polymer and the anionic polymer form a coacervate complex in a fluid;

wherein the anionic polymer comprises a polycarbonate backbone comprising anionic functional groups bound to the polycarbonate backbone; and

wherein the cationic polymer comprises:

a polymer backbone;

at least one therapeutic functional group bound to the polymer backbone, wherein the at least one therapeutic functional group provides at least one of an antimicrobial functionality or an anticancer functionality of the therapeutic agent; and

a biotin-based functional group bound to an end of the polymer backbone, wherein the biotin-based functional group being bound to the end of the polymer backbone improves the at least one of the antimicrobial functionality or the anticancer functionality of the therapeutic agent.

2 . The therapeutic agent of claim 1 , wherein the at least one therapeutic functional group comprises guanidinium moieties.

3 . The therapeutic agent of claim 1 , wherein the therapeutic agent facilitates necrosis of bacteria cells.

4 . The therapeutic agent of claim 1 , wherein the therapeutic agent facilitates autophagy of cancer cells.

5 . The therapeutic agent of claim 1 , wherein the biotin-based functional group comprises biotinol.

6 . The therapeutic agent of claim 1 , wherein the at least one therapeutic functional group comprises at least one member selected from the group consisting of: a guanidinium moiety, a thiol moiety, and a carboxylic acid moiety.

7 . The therapeutic agent of claim 1 , wherein cationic polymer has a chemical structure characterized by Formula I:

wherein n represents an integer between 10 and 50,

wherein R 1 comprises the biotin-based functional group, and

wherein R 2 comprises a spacer group.

8 . The therapeutic agent of claim 1 , wherein the cationic polymer has a chemical structure characterized by Formula II:

wherein n represents an integer between 10 and 50.

9 . The therapeutic agent of claim 1 , wherein the coacervate complex exhibits reduced hemotoxicity relative to the cationic polymer alone.

10 . The therapeutic agent of claim 1 , wherein the anionic functional groups are selected from the group consisting of: sulfonate groups, carboxylate groups, and phosphoric acid groups.

11 . The therapeutic agent of claim 1 , wherein the anionic polymer comprises a polyethylene glycol tail.

12 . The therapeutic agent of claim 11 , wherein the polyethylene glycol tail is formed around the cationic polymer of the coacervate complex.

13 . The therapeutic agent of claim 1 , wherein the coacervate complex comprises a circular or spherical nanoparticle structure.

14 . The therapeutic agent of claim 1 , wherein the coacervate complex comprises a nanoparticle structure having a size from about 70 nanometers (nm) to about 200 nm.

15 . A therapeutic, agent, comprising:

a cationic polymer and an anionic polymer;

wherein the cationic polymer and the anionic polymer form a coacervate complex in a fluid;

wherein the anionic polymer comprises a polycarbonate backbone comprising anionic functional groups bound to the polycarbonate backbone; and

wherein the cationic polymer has a chemical structure characterized by Formula I:

wherein n represents an integer between 10 and 50,

wherein R 1 comprises a biotin-based functional group that improves at least one of an antimicrobial functionality or an anticancer functionality provided by at least one therapeutic functional group of the cationic polymer, and

wherein R 2 comprises a spacer group.

16 . The therapeutic agent of claim 15 , wherein the therapeutic agent is an anticancer agent.

17 . The therapeutic agent of claim 15 , wherein the therapeutic agent is an antimicrobial agent.

18 . A therapeutic agent, comprising:

a cationic polymer and an anionic polymer;

wherein the cationic polymer and the anionic polymer form a coacervate complex in a fluid;

wherein the anionic polymer comprises a polycarbonate backbone comprising anionic functional groups bound to the polycarbonate backbone; and

wherein the cationic polymer has a chemical structure characterized by Formula I:

wherein n represents an integer between 10 and 50, and

where the therapeutic gent is effective against a plurality of different cancer cell lines.

19 . The therapeutic agent of claim 18 , wherein the plurality of different cancer cell lines comprises cancer cell line BT-474.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 9, 2021
From: YANG, YI YAN; VOO, ZHI XIANG
To: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
Reel/Frame 057425/0610 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 9, 2021
From: HEDRICK, JAMES L.; PARK, NATHANIEL H.
To: INTERNATIONAL BUSINESS MACHINES CORPORATION
Reel/Frame 057445/0951 →
Continuity (2)
Division 16201155 · Nov 27, 2018
Related Publication 20210401995A1 · Dec 30, 2021
References Cited (69)
US 7329638B2 · Yang et al. · 2008 [cited by applicant]
US 8709483B2 · Farokhzad et al. · 2014 [cited by applicant]
US 11007216B2 · Hedrick · 2021 [cited by examiner]
US 11167036B2 · Hedrick et al. · 2021 [cited by applicant]
US 20050059031A1 · Bruchez et al. · 2005 [cited by applicant]
US 20070053934A1 · Kallenbach et al. · 2007 [cited by applicant]
US 20100280219A1 · Cooley · 2010 [cited by examiner]
US 20140301968A1 · Coady et al. · 2014 [cited by applicant]
US 20160338356A1 · Chin · 2016 [cited by examiner]
WO 2006023207A2 · 2006 [cited by applicant]
Muhammad (Chemical Communication, 2017, 53, 9971-9974) (Year: 2017). [cited by examiner]
Velasco et al., “Comparative Study of Clinical Characteristics of Neutropenic and Non-Neutropenic Adult Cancerpatients with Bloodstream Infections”, European Journal of Clinical Microbiology & Infectious Diseases , vol.… [cited by applicant]
Wang et al., “Biodegradable Functional Polycarbonate Micelles for Controlled Release of Amphotericin B”, Acta Biomaterialia, Jul. 12, 2016, 10 pages. [cited by applicant]
Weiss et al., “Macrophage Defense Mechanisms Against Intracellular Bacteria”, Immunological Reviews, vol. 264, 2015, pp. 182-203. [cited by applicant]
Wong et al., “Bactericidal and Virucidal Ultrathin Films Assembled Layer by Layer from Polycationic N-alkylated Polyethylenimines and Polyanions”, Biomaterials, 2010, vol. 31, pp. 4079-4087. [cited by applicant]
Yang et al., “The Role of Non-covalent Interactions in Anticancer Drug Loading and Kinetic Stability of Polymeric Micelles”, Biomaterials, vol. 33, 2012, pp. 2971-2979. [cited by applicant]
Zhang et al., “Antimicrobial Metallopolymers and their Bioconjugates with Conventional Antibiotics Against Multidrug-resistant Bacteria”, Journal of the American Chemical Society, vol. 136, 2014, pp. 4873-4876. [cited by applicant]
Kim et al., “Synthesis and Evaluation of Biotin-conjugated pH-responsive Polymeric Micelles as Drug Carriers”, Int J Pharm, vol. 427, No. 2, May 10, 2012, pp. 435-442, doi: 10.1016/j.ijpharm.2012.01.034, Epub, Feb. 7, 2… [cited by applicant]
Minko et al., “Enhancing the Anticancer Efficacy of Camptothecin Using Biotinylated Poly (Ethylene Glycol) Conjugates in Sensitive and Multidrug-resistant Human Ovarian Carcinoma Cells”, Cancer Chemother Pharmacology, v… [cited by applicant]
Ramathan et al., “Targeted PEG-based Bioconjugates Enhance the Cellular Uptake and Transport of a HIV-1 TAT Nonapeptide”, Journal of Controlled Release, vol. 77, No. 3, Dec. 13, 2001, 1 page. [cited by applicant]
Walker et al., “Biotinylation Facilitates the Uptake of Large Peptides by [cited by applicant]
Attia et al., “The Effect of Kinetic Stability on Biodistribution and Anti-tumor Efficacy of Drug-loaded Biodegradable Polymeric Micelles”, Biomaterials, vol. 34, 2013, pp. 3132-3140. [cited by applicant]
Belon et al., “Intramacrophage Survival for Extracellular Bacterial Pathogens: Mgtc as a Key Adaptive Factor”, Frontiers in Cellular and Infection Microbiology, vol. 61, No. 52, May 17, 2016, 5 pages. [cited by applicant]
Belon et al., “Intracellular Phase for an Extracellular Bacterial Pathogen: Mgtc Shows the Way”, Microbial Cell, vol. 2, No. 9, Sep. 2015, 3 pages. [cited by applicant]
Buyck et al., “RX-P873, a Novel Protein Synthesis Inhibitor, Accumulates in Human THP-1 Monocytes and is Active against Intracellular Infections by Gram-positive ( [cited by applicant]
Cheng et al., “Broad-spectrum Antimicrobial/Antifouling Soft Material Coatings using Poly(elhylenimine) as a Tailorable Scaffold”, Biomacromolecules, Jun. 3, 2015, 35 pages. [cited by applicant]
Chin et al., “Biodegradable Broad-spectrum Antimicrobial Polycarbonates: Investigating the Role of Chemical Structure on Activity and Selectivity”, Macromolecules, vol. 46, 2013, pp. 8797-8807. [cited by applicant]
Chin et al., “A Macromolecular Approach to Eradicate Multidrug Resistant Bacterial Infections while Mitigating Drug Resistance Onset”, Nature Communications, vol. 9, No. 917, Mar. 2, 2018, 14 pages. [cited by applicant]
Coady et al., “Enhancement of Cationic Antimicrobial Materials via Cholesterol Incorporation”, Advance Healthcare Materials, vol. 3, 2014, pp. 882-889. [cited by applicant]
Cooley et al., “Oligocarbonate Molecular Transporters: Oligomerization-Based Syntheses and Cell-Penetrating Studies”, Journal of the American Chemical Society, vol. 131, No. 45, 2009, pp. 16401-16403. [cited by applicant]
Engler et al., “The Synthetic Tuning of Clickable pH Responsive Cationic Polypeptides and Block Copolypeptides”, Soft Matter, vol. 7, 2011, pp. 5627-5637. [cited by applicant]
Engler et al., “Polycarbonate-Based Brush Polymers with Detachable Disulfide-Linked Side Chains”, ACS Macro Letters, vol. 2, 2013, pp. 332-336. [cited by applicant]
Engler et al., “Antimicrobial Polycarbonates: Investigating the Impact of Balancing Charge and Hydrophobicity Using a Same-Centered Polymer Approach”, Biomacromolecules, Aug. 19, 2013, 9 pages. [cited by applicant]
Feng et al., “Construction of Functional Aliphatic Polycarbonates for Biomedical Applications”, Progress in Polymer Science, vol. 37, 2012, pp. 211-236. [cited by applicant]
Fukushima et al., “Broad Spectrum Antimicrobial Supramolecular Assemblies with Distinctive Size and Shape”, American Chemical Society NANO, vol. 6, No. 10, 2012, pp. 9191-9199. [cited by applicant]
Gabriel et al., “Synthetic Mimic of Antimicrobial Peptide with Nonmembrane-Disrupting Antibacterial Properties”, Biomacromolecules, vol. 9, No. 11, 2008, pp. 2980-2983. [cited by applicant]
Gootz, T. D., “The Global Problem of Antibiotic Resistance”, Critical Reviews in Immunology, vol. 30, No. 1, 2010, 2 pages. [cited by applicant]
Han et al., “Polymer/Peptide Complex-Based Sensor Array Discriminates Bacteria in Urine”, Angenwandte Chemie International Edition, 2017, 7 pages. [cited by applicant]
Hidron et al., “Infection Control and Hospital Epidemiology”, Chicago Journals, vol. 30, No. 1, Jan. 2009, 2 pages. [cited by applicant]
Ichiyama et al., “Cooperative Orthogonal Macromolecular Assemblies with Broad Spectrum Antiviral Activity, High Selectivity, and Resistance Mitigation”, Macromolecules, vol. 49, 2016, pp. 2618-2629. [cited by applicant]
Ikler et al., “Tuning the Hemolytic and Antibacterial Activities of Amphiphilic Polynorbornene Derivatives”, Journal of the American Chemical Society, vol. 126, 2004, pp. 15870-15875. [cited by applicant]
Insua et al., “Enzyme-responsive Polyion Complex (PIC) Nanoparticles for the Targeted Delivery of Antimicrobial Polymers”, Polymer Chemistry, Jan. 26, 2016, 7 pages. [cited by applicant]
Kharazmi, A., “Mechanisms Involved in the Evasion of the Host Defence by Pseudomonas aeruginosa”, Immunology Letters, vol. 30, 1991, pp. 201-206. [cited by applicant]
Kuroda et al., “Amphiphilic Polymethacrylate Derivatives as Antimicrobial Agents”, Journal of the American Chemical Society, vol. 127, 2005, pp. 4128-4129. [cited by applicant]
Lee et al., “Block Copolymer Mixtures as Antimicrobial Hydrogels for Biofilm Eradication”, Biomaterials, vol. 34, 2013, pp. 10278-10286. [cited by applicant]
Li et al., “Broad-Spectrum Antimicrobial and Biofilm-Disrupting Hydrogels: Stereocomplex-Driven Supramolecular Assemblies”, Angenwandte Chemie International Edition, vol. 52, 2013, pp. 674-678. [cited by applicant]
Liu et al., “Nontoxic Membrane-Active Antimicrobial Arylamide Oligomers”, Angewandte Chemie International Edition, vol. 116, 2004, pp. 1178-1182. [cited by applicant]
Lyczak et al., “Establishment of Pseudomonas aeruginosa Infection: Lessons From a Versatile Opportunist”, Microbes and Infection, vol. 2, 2000, pp. 1051-1060. [cited by applicant]
Marr et al., “Antibacterial Peptides for Therapeutic Use: Obstacles and Realistic Outlook”, Current Opinion in Pharmacology, vol. 6, 2006, pp. 468-472. [cited by applicant]
Mittal et al., “Otopathogenic Pseudomonas aeruginosa Enters and Survives Inside Macrophages”, Frontiers in Microbiology, vol. 7, No. 1828, Nov. 2016, 15 pages. [cited by applicant]
Ng et al., “Synergistic Co-Delivery of Membrane-Disrupting Polymers with Commercial Antibiotics against Highly Opportunistic Bacteria”, Advanced Materials, vol. 25, 2013, pp. 6730-6736. [cited by applicant]
Ng et al., “Antimicrobial Polycarbonates: Investigating the Impact of Nitrogen-Containing Heterocycles as Quaternizing Agents”, Macromolecules, Dec. 26, 2013, 7 pages. [cited by applicant]
Lienkamp et al., “Antimicrobial Polymers Prepared by ROMP with Unprecedented Selectivity: A Molecular Construction Kit Approach”, Journal of the American Chemical Society, vol. 130, No. 30, Jul. 30, 2008, pp. 9836-9843. [cited by applicant]
Ong et al., “Design and Synthesis of Biodegradable Grafted Cationic Polycarbonates as Broad Spectrum Antimicrobial Agents”, Journal of Polymer Science, Part A: Polymer Chemistry, vol. 54, 2016, pp. 1029-1035. [cited by applicant]
Rada et al., “Interactions between Neutrophils and Pseudomonas aeruginosa in Cystic Fibrosis”, Pathogens, vol. 6, 2017, 24 pages. [cited by applicant]
Percival et al., “HCAI, Medical Devices and Biofilms: Risk, Tolerance and Control”, Journal of Medical Microbiology, Feb. 10, 2015, 31 pages. [cited by applicant]
Pratt et al., “Exploration, Optimization, and Application of Supramolecular Thiourea-Amine Catalysts for the Synthesis of Lactide (Co)polymers”, Macromolecules, vol. 39, 2006, pp. 7863-7871. [cited by applicant]
Pratt et al., “Tagging Alcohols With Cyclic Carbonate: a Versatile Equivalent of (Meth)acrylate for Ring-Opening Polymerization”, Chemical Communications, 2008, pp. 114-116. [cited by applicant]
Qiao et al., “Highly Dynamic Biodegradable Micelles Capable of Lysing Gram-positive and Gram-negative Bacterial Membrane”, Biomaterials, vol. 33, 2012, pp. 1146-1153. [cited by applicant]
Ruden et al., “Synergistic Interaction between Silver Nanoparticles and Membrane-permeabilizing Antimicrobial Peptides”, Antimicrobial Agents and Chemotherapy, vol. 53, No. 8, Aug. 2009, pp. 3538-3540. [cited by applicant]
Tan et al., “Broad Spectrum Macromolecular Antimicrobials with Biofilm Disruption Capability and In Vivo Efficacy”, Advanced Healthcare Materials, 1601420, 2017, 9 pages. [cited by applicant]
Tempelaar et al., “Synthesis and Post-polymerisation Modifications of Aliphatic Poly(Carbonate)s Prepared by Ring-opening Polymerisation”, Chemical Society Reviews, 2012, 24 pages. [cited by applicant]
Tew et al., “De novo Design of Biomimetic Antimicrobial Polymers”, Proceedings of the National Academy of Sciences, vol. 99, No. 8, Apr. 16, 2002, pp. 5110-5114. [cited by applicant]
Tra et al., “Glycans in Pathogenic Bacteria—Potential for Targeted Covalent Therapeutics and Imaging Agents”, Chemical Communication, vol. 50, 2014, pp. 4659-4673. [cited by applicant]
Tynan et al., “Macrophage Migration Inhibitory Factor Enhances Pseudomonas aeruginosa Biofilm Formation Potentially Contributing to Cystic Fibrosis Pathogenesis”, The FASEB Journal, vol. 31, Aug. 2017, 10 pages. [cited by applicant]
Yang et al., “Supramolecular Nanostructures Designed for High Cargo Loading Capacity and Kinetic Stability”, Nano Today, vol. 5, 2010, pp. 515-523. [cited by applicant]
Non-Final Office Action received for U.S. Appl. No. 16/201,155 dated Jan. 28, 2021, 46 pages. [cited by applicant]
United States Notice of Allowance dated Jun. 30, 2021, 10 pages, in U.S. Appl. No. 16/201,155. [cited by applicant]
United States Requirement for Restriction/Election dated Sep. 21, 2020, 11 pages in U.S. Appl. No. 16/201,155. [cited by applicant]